Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Gavreto
Descriptions
Pralsetinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer (NSCLC) and in patients whose tumors have RET fusion-positive genes. Your doctor will perform a test to check for the RET gene fusion before you use this medicine.
Pralsetinib is also used to treat advanced or metastatic (cancer that has already spread) medullary thyroid cancer (MTC) in patients whose tumors have abnormal RET (RET-mutant) genes. Your doctor will perform a test to check for the abnormal RET gene before you use this medicine. It is used in patients who needs a medicine by mouth or injection.
Pralsetinib is also used to treat advanced or metastatic (cancer that has already spread) thyroid cancer in patients whose tumors have RET fusion-positive genes. Your doctor will perform a test to check for the RET gene fusion before you use this medicine. It is used in patients who needs a medicine by mouth or injection and have received radioactive iodine but did not work.
Pralsetinib belongs to the group of medicines called antineoplastics (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: April 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.